5 completed, 1 active not recruiting, 1 unknown. 7 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 5, Active not recruiting 1, Unknown 1 |
| Phase 1 | 5 | Completed 3, Active not recruiting 1, Unknown 1 |
Follow SK Bioscience Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults. Test Drug 1-1 (GBP511 low dose), Test Drug 1-2 (GBP511 mid dose), Test Drug 1-3 (GBP511 high dose) - Healthy Participants, Sarbecovirus | Phase 1 / Phase 2 | Active not recruiting | SK Bioscience Co., Ltd. | 368 | 2026-01-28 | 2026-09-09 |
| A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults GBP560-A, GBP560-B, IXIARO - Japanese Encephalitis Virus Disease | Phase 1 / Phase 2 | Completed | SK Bioscience Co., Ltd. | 161 | 2025-02-24 | 2026-09-11 |
| Mixed Schedule Study of Live Oral Rotavirus Vaccines and Trivalent P2-VP8 Subunit Rotavirus Vaccine RV3-BB, Trivalent P2-VP8, Rotarix - Rotavirus Vaccine | Phase 2 | Completed | PATH | 850 | 2021-02-22 | 2022-11-29 |
| Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19) GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 1, GBP510 (RBD 10μg/dose) - Stage 1, Normal saline (0.9% sodium chloride solution) - Stage 1 - COVID-19 (Healthy Volunteers) | Phase 1 / Phase 2 | Unknown | SK Bioscience Co., Ltd. | 328 | 2021-02-03 | 2022-05-10 |
| Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19) GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 1, Normal saline (0.9% sodium chloride solution) - Stage 1, GBP510 adjuvanted with Alum (RBD 25μg/dose) - Stage 1 - COVID-19 (Healthy Volunteers) | Phase 1 / Phase 2 | Completed | SK Bioscience Co., Ltd. | 260 | 2021-01-20 | 2023-04-18 |
| Immunogenicity and Safety Study of NBP615 in Healthy Female NBP615, Gardasil - Cervical Cancer | Phase 1 / Phase 2 | Completed | SK Bioscience Co., Ltd. | 200 | 2018-12-22 | 2021-10-01 |
| Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine Vi-DT, FluQuadri™, 0.9% sodium chloride isotonic solution - Typhoid | Phase 2 | Completed | International Vaccine Institute | 285 | 2018-04-18 | 2021-08-27 |
COVID-19 (2) · Encephalitis, Japanese (1) · Typhoid Fever (1) · Uterine Cervical Neoplasms (1)
Saline Solution (4) · Sodium Chloride (2) · BNT162 Vaccine (1) · Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (1) · RIX4414 vaccine (1) · aluminum sulfate (1)
South Korea (3) · Australia (2) · New Zealand (1) · Philippines (1) · South Africa (1)
Hee Jin Cheong (2) · Maria Rosario Capeding, MD (1) · Stanley Cryz, PhD (1)
PMID 33873199, PMID 31585725, PMID 33150320, PMID 35879941, PMID 40446606